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ABSTRACT
Dairy product consumption is often associated with 
negative effects because of its naturally high levels of 
saturated fatty acids. However, recent research has 
shown that dairy lipids possess putative bioactivity 
against chronic inflammation. Inflammation triggers 
the onset of several chronic diseases, including cardio-
vascular disease, type 2 diabetes mellitus, obesity, and 
cancer. This review discusses the anti-inflammatory 
properties of dairy lipids found in milk, yogurt, and 
cheese, and it examines them in relation to their impli-
cations for human health: their protective effects and 
their role in pathology. We also consider the effect of 
lipid profile alteration in dairy products—by using ru-
minant dietary strategies to enrich the milk, or by lipid 
fortification in the products. We critically review the 
in vivo, in vitro, ex vivo, and epidemiological studies 
associated with these dairy lipids and their role in vari-
ous inflammatory conditions. Finally, we discuss some 
suggestions for future research in the study of bioactive 
lipids and dairy products, with reference to the novel 
field of metabolomics and epidemiological studies.
Key words: inflammation, cardiovascular disease, 
lipids, dairy
INTRODUCTION
Increasing evidence supports the pivotal function of 
nutrition in the development of chronic diseases such 
as cardiovascular disease (CVD), cancer, insulin resis-
tance, and obesity (Shingfield et al., 2008; Mozaffar-
ian et al., 2011). In the public and scientific domains, 
people see dairy fat as a negative component of milk 
and dairy products, predominantly because they are 
energy-dense, rich in cholesterol and saturated fat 
(Kratz et al., 2013). Dairy products are conventionally 
perceived as having an adverse effect on health (Risérus 
et al., 2009), particularly in relation to CVD, which is 
a leading cause of death in developed societies due to 
factors such as diet, stress, obesity, sedentary lifestyle, 
type 2 diabetes, and smoking, among others (Siurana 
and Calsamiglia, 2016). In this review, we discuss the 
nutritional value of the lipid components of milk and 
dairy products to highlight the anti-inflammatory ac-
tivities of lipids such as CLA, PUFA, and polar lipids.
THE BIOCHEMISTRY OF INFLAMMATION
Inflammation is a necessary process of the innate 
immune system and is required for physiological re-
sponses such as initiating tissue repair and eliminat-
ing pathogenic insults, but excessive inflammation can 
lead to tissue injury (Salajegheh, 2016). Inflammation 
is a complex biological process that involves numerous 
interactions between different cell types, as well as the 
production of and responses to several chemical media-
tors (Calder et al., 2011). It is an integral feature of 
atherosclerosis, CVD, cancer, type 2 diabetes, obesity, 
and even Alzheimer’s disease (Ross, 1999; Libby et al., 
2002; Tselepis and Chapman, 2002; Greenberg and 
Obin, 2006; Reuter et al., 2010; Nestel et al., 2012; Van 
Eldik et al., 2016). A maladaptive diet and lifestyle are 
the dominant underlying causes of systemic inflamma-
tion (de Koning and Rabelink, 2002; O’Keefe et al., 
2008). Processed and energy-rich foods and drinks can 
lead to exaggerated postprandial elevations in plasma 
glucose and triglycerides. Due to our increased intake 
of these foods in Western societies, postprandial hy-
perlipemia and hyperglycemia are common (O’Keefe 
and Bell, 2007), and postprandial lipemia in itself is 
an independent risk factor for CVD, obesity, metabolic 
syndrome, and type 2 diabetes (Lecomte et al., 2015). 
These spikes in triglycerides and glucose can generate 
an excess of plasma reactive oxygen species that can 
initiate pro-inflammatory reactions (de Koning and Ra-
belink, 2002; Hyson et al., 2003; O’Keefe et al., 2008). 
Activated immune cells can promote or suppress in-
flammation; reducing inflammation is essential to avoid 
long-lasting damage to host tissue (Nathan, 2002). 
Mediators of inflammation are central to maintaining 
equilibrium in an acute inflammatory response. If an 
acute inflammatory response is not resolved, it will 
continue, and the subsequent inflammatory microen-
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vironment will disrupt tissue homeostasis, leading to a 
low-grade chronic inflammatory condition (Nasopoulou 
and Zabetakis, 2015).
Atherosclerosis is a chronic progressive vascular 
disease that develops through the formation of foam 
cells, atherosclerotic plaque, fissure, erosion, and 
rupture, leading to a major cardiovascular event. 
Endothelial dysfunction, regarded as the initial stage 
of atherosclerosis development (Mudau et al., 2012), 
is characterized by oxidative stress and gives rise to 
decrease in the bioavailability of vasodilators such as 
nitric oxide (Bonetti et al., 2003). This in turn causes 
increased endothelial permeability and expression of 
pro-inflammatory cells (e.g., monocytes; Tselepis and 
Chapman, 2002). Due to the phenotypic polarization 
of monocytes and the activation of other immune cells, 
the expression of pro-inflammatory and pro-thrombotic 
factors is increased, including reactive oxygen species, 
metalloproteases, phospholipases, cytokines, bioactive 
lipids such as platelet-activating factor (PAF), and tis-
sue factors such as tumor necrosis factor-α (TNF-α; 
Libby, 1995; Tselepis and Chapman, 2002). Chronic 
exposure to CVD risk factors such as hyperlipemia, hy-
perglycemia, smoking, obesity, hypertension, or dietary 
factors initializes the onset of endothelial dysfunction 
(Deanfield et al., 2007).
High levels of serum lipids, particularly low-density 
lipoprotein cholesterol, have long been associated 
with the development of atherosclerosis (Choy et al., 
2004). Products of lipid oxidation, such as oxidized 
phospholipids, are recognized as chronic inducers of 
inflammation, characteristic of atherosclerosis (Boch-
kov, 2007). However, some oxidized phospholipids may 
possess protective effects against inflammation (Mau-
erhofer et al., 2016). Dietary intake of lipids plays a 
key role in suppressing inflammatory processes. Dairy 
products were once thought to be detrimental to health 
by inducing inflammatory diseases such as CVD, but 
recent evidence suggests that they are associated with 
a beneficial or neutral effect on inflammation (Labonté 
et al., 2013). Nevertheless, the mechanisms underlying 
the observed beneficial effects of specific dairy product 
consumption and inflammation remain unclear (Da 
Silva and Rudkowska, 2015).
Platelet-activating factor is a crucial potent inflam-
matory and thrombotic phospholipid mediator of 
atherosclerosis (Demopoulos et al., 1979; Demopoulos 
et al., 2003). It is the most potent lipid mediator of 
inflammation (Prescott et al., 2000) and is essential 
for the activation of leukocytes and their binding to 
endothelial cells (Liapikos et al., 1994). Lipid microcon-
stituents of specific foods exert in vitro anti-inflamma-
tory and antithrombotic activities by inhibiting PAF 
(Zabetakis, 2013). However, research into the effects of 
dairy products on inflammatory mediators such as PAF 
has been limited (Huth and Park, 2012).
Inflammation is firmly linked with inflammatory 
bowel diseases (Lasry et al., 2016) and the develop-
ment of colorectal cancer—the third most commonly 
diagnosed cancer in the Western world (García-Barros 
et al., 2014). Dairy product consumption has been asso-
ciated with protective effects against colorectal cancer 
and other inflammatory diseases (Panagiotakos et al., 
2010; Aune et al., 2012; Crichton and Alkerwi, 2014; 
Rashidi Pour Fard et al., 2015), although this is some-
times controversial. These beneficial effects have been 
attributed to specific short-chain and medium-chain 
SFA, dairy trans-fatty acids, and milk proteins, which 
may have a synergistic effect with other micronutrients 
such as calcium, magnesium, and potassium (Da Silva 
and Rudkowska, 2015).
ANTI-INFLAMMATORY PROPERTIES OF LIPIDS  
IN DAIRY PRODUCTS
In Vitro
In vitro studies of dairy-derived fatty acids generally 
focus on the effects of α-linolenic acid, docosahexae-
noic acid, eicosapentaenoic acid, linoleic acid, and 
their derivatives. For this review, we have chosen to 
highlight the putative anti-inflammatory properties of 
dairy-derived polar lipids. The polar lipid fractions of 
food consist of phospholipids and sphingolipids, located 
in the milk fat globule membrane of dairy products. 
This is a complex biological membrane surrounding the 
fat globules in milk, primarily consisting of membrane-
specific proteins and polar lipids (Phan et al., 2016). 
The majority of studies investigating the effects of po-
lar lipids on inflammation have been performed using 
soy-extracted polar lipids (Castro-Gómez et al., 2015). 
Research by Antonopoulou et al. (1996) on cow’s milk 
and yogurt has shown that both products contain lipids 
capable of inhibiting PAF-induced platelet aggregation.
The anti-inflammatory activities of lipids in goat and 
sheep products have been studied in traditional Greek 
Ladotyri and Kefalotyri sheep cheeses (Tsorotioti et al., 
2014), and the lipid fractions of both cheeses exhib-
ited inhibitory activity toward PAF-induced platelet 
aggregation. Further analysis of the lipid fractions 
in both cheeses, by thin layer chromatography, has 
shown that the most biologically active lipid fractions 
contained sphingomyelin, phosphatidylcholine, and 
phosphatidylethanolamine lipid derivatives. However, 
these lipid fractions do not always present as a typical 
phospholipid structure; they share a similar structure 
to phosphatidylcholine derivatives as reported by Naso-
poulou et al. (2014). Researchers have demonstrated 
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that phosphatidylcholine has several anti-inflammatory 
effects (Treede et al., 2007; Erős et al., 2009).
Poutzalis et al. (2016) compared the PAF-inhibiting 
properties of goat products (milk, yogurt, and cheese), 
and all goat samples possessed PAF inhibitors. The 
resulting data indicated an increasing trend of PAF 
inhibition during lipolysis (i.e., incubation of milk to 
yogurt and cheese). This trend has been attributed to 
fermentation involving microorganisms such as Lacto-
bacillus delbrueckii ssp. bulgaricus and Streptococcus 
thermophilus. The animal origin of milk plays an im-
portant role, as suggested by Megalemou et al. (2017); 
the most potent PAF inhibitors were found in yogurts 
produced from ovine and caprine milk, as opposed to 
yogurts from bovine milk.
In Vivo
Dillehay et al. (1994) has shown that diets contain-
ing varying amounts of milk-derived sphingomyelin 
reduced the number of aberrant crypt foci (pre-neo-
plastic lesions) in the colon of carcinogen-treated mice. 
Synthetic sphingomyelin also exhibited suppression of 
aberrant crypt foci, comparable with the sphingomy-
elin compounds of milk origin, indicating that pos-
sible co-purified contaminants were not responsible 
for the resulting anti-inflammatory activity (Schmelz 
et al., 1997). Further studies have used sphingomyelin 
isolated from powdered low-fat milk, buttermilk, and 
glycerophospholipids (Schmelz et al., 1996; Schmelz et 
al., 2000). Further in vivo experiments by Mazzei et 
al. (2011) examined the suppression of dextran sodium 
sulfate–induced colitis and azoxymethane-induced 
colon cancer by dietary sphingomyelin from a bovine 
milk source in mice that lacked or possessed functional 
peroxisome-activated receptor γ (PPAR-γ) in intesti-
nal, epithelial, and immune cells. The sphingomyelin 
diet reduced inflammation and the development of 
colon cancer. These findings were linked to improved 
preservation of the colonic microscopic structure and 
an increased survival rate in the mice. Several genes 
associated with promoting cancer and genes that ex-
erted anti-tumor functions were down- or upregulated, 
respectively, by dietary sphingomyelin in PPAR-γ-
expressing mice. This finding suggests that PPAR-γ 
may play a protective role in the prevention of colon 
cancer with dietary sphingomyelin. This group has also 
shown that sphingomyelin may be beneficial in prevent-
ing the progression of breast cancer (Simon et al., 2010) 
and ovarian cancer (Babahosseini et al., 2012).
Obesity is also strongly associated with increased risk 
of CVD and cancer. A study by Lecomte et al. (2016) 
found that a high-fat diet incorporating milk polar 
lipids fed to mice did not induce white adipose tissue 
hypertrophy and mRNA markers of inflammation, in 
contrast to mice fed high-fat diets incorporating soy-
bean polar lipids (lecithin). The study observed that 
soybean polar lipids led to features of obesity-induced 
adipose tissue dysfunction (hyperplasia and hypertro-
phy) combined with infiltration by inflammatory cells, 
increased expression of TNF-α, mono-chemoattractant 
protein-1, LPS-binding protein, and leptin. Although 
the dietary lipid intake was similar, these inflammatory 
markers were not increased with milk polar lipid con-
sumption. Instead, milk polar lipids exhibited protec-
tive anti-inflammatory activity with lower gene expres-
sion of a marker of macrophage infiltration (CD68) in 
white adipose tissue and lower plasma concentrations 
of LPS-binding protein, a transporter of endotoxins. 
The study also deduced that mice that consumed milk 
polar lipids might have had a stronger colon barrier 
due to an increase in mucus-producing goblet cells 
in the colon. Impairment of the intestinal barrier can 
contribute to the passage of endotoxins into the cir-
culatory system, leading to the activation of several 
inflammatory pathways (Cani et al., 2012). Lecomte 
et al. (2016) hypothesized that the stronger intestinal 
barrier induced prevented high-fat-induced macrophage 
infiltration in the white adipose tissue, preventing the 
onset of chronic inflammation. A similar increase in 
goblet cells was observed in another study in mice fed a 
high-fat diet supplemented with pasture-derived dairy 
cream versus mice fed a high-fat diet and standard 
dairy cream (Benoit et al., 2014).
Various groups (Lecomte et al., 2016; Nilsson, 2016; 
Norris et al., 2016) have attributed the anti-inflamma-
tory effects of milk polar lipids to the presence of the 
sphingomyelin-derived lipids. Dietary sphingomyelin 
has exhibited the ability to repress inflammation-driven 
colorectal cancer (Mazzei et al., 2011) by modulating 
the inflammatory response (El Alwani et al., 2006). 
Sphingolipid metabolites such as sphingosine-1-phos-
phate, ceramide-1-phosphate, and ceramide are crucial 
biologically active signaling molecules involved in the 
regulation of key physiological functions and implicated 
in a multitude of pathological processes and inflam-
mation-associated diseases (Hannun and Obeid, 2008; 
Gomez-Muñoz et al., 2016). However, current views are 
that these metabolites may contribute not only to anti-
inflammatory responses, but also to pro-inflammatory 
ones.
Gomez-Muñoz et al. (2016) indicated in their review 
that ceramides are of a particular concern, because 
they can cause inflammatory responses from several 
cells. The role of sphingosine-1-phosphate in inflam-
mation is controversial, whereas depending on the cell 
type, ceramide-1-phosphate can have either anti or 
pro-inflammatory activity. Further dietary intervention 
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studies are required to illustrate the effect of individual 
sphingolipids in modulating inflammation in human 
responses.
Ex Vivo
Relatively few published ex vivo studies have exam-
ined the effects of conventional dairy product consump-
tion on inflammatory markers in healthy or diseased 
humans. Table 1 presents several selected clinical trials 
from 2009 to 2016 that measured the effects of dairy 
consumption on inflammation markers. With the ex-
ception of Labonté et al. (2014), the trials assessed the 
effects only in obese or overweight participants. The 
resulting outcomes of these trials are conflicting and 
indicate no clear consensus on how dairy consumption 
affects inflammatory markers in obese or healthy popu-
lations. It must be noted that many of the studies as-
sessed the pro- and anti-inflammatory capacities of low-
fat milk and dairy products. Global trends show that 
full-fat dairy consumption has fallen since the 1970s, 
and low-fat dairy consumption has increased (Feeney et 
al., 2016). The ex vivo studies presented here neglected 
the fact that the fat components of bovine, ovine, and 
caprine milk have significant nutritional value and pos-
sess bioactive lipids with anti-inflammatory properties 
(Contarini and Povolo, 2013; Tsorotioti et al., 2014; 
Poutzalis et al., 2016).
Conjugated linoleic acid is a collective term for several 
isomers of linoleic acid (Bhattacharya et al., 2006) that 
possess putative modulating effects on pro- and anti-
inflammatory responses (Reynolds and Roche, 2010). 
The richest natural dietary sources of CLA for human 
consumption are milk, dairy products, meat, and meat 
products (Benjamin and Spener, 2009). Rumenic acid, 
the cis-9,trans-11 isomer, is the predominant form of 
CLA, representing over 90% of total CLA in ruminant 
milk fat (Savoini et al., 2010). Trans-10,cis-12 CLA is 
another common isomer that is the focus of many stud-
ies, and it accounts for 1 to 10% of total CLA (Reyn-
olds and Roche, 2010). Consumption of trans-10,cis-12 
CLA is associated with anti-adipogenic effects in in 
vivo and in vitro models (Park et al., 1999; Kang et al., 
2003; Yeganeh et al., 2016); however, clinical trials have 
been inconsistent in their results (Tricon et al., 2006; 
Whigham et al., 2007; Plourde et al., 2008). The total 
fat and CLA content in ruminant milk varies between 
species and depends on several biological and environ-
mental factors (Lock and Bauman, 2004; Bainbridge et 
al., 2016). Conjugated linoleic acid is an intermediate 
product of the microbial biohydrogenation of linoleic 
acid to stearic acid in the rumen of animals Buccioni 
et al. (2012) and is produced endogenously in mam-
mary tissue from trans vaccenic acid (Yaqoob, 2015). 
The diet of a dairy animal is the main factor affecting 
the CLA content of its milk (Siurana and Calsamiglia, 
2016). Despite inconsistent data from CLA supplement 
studies, researchers have started to develop processes 
to naturally increase the cis-9,trans-11 CLA content of 
milk and dairy products (Yaqoob, 2015). This has led 
to a surge in the enrichment of milk and dairy products 
with CLA by researchers and commercial entities who 
aim to produce novel functional foods.
In animal models, CLA has been reported to possess 
anti-atherogenic, anti-carcinogenic, and anti-inflamma-
tory properties; it may also reduce adipose tissue mass 
and protect against the final stages of systemic lupus 
erythematosus (Kritchevsky et al., 2000; Reynolds and 
Roche, 2010; Bruen et al., 2017). However, studies are 
inconsistent concerning the effects of CLA consump-
tion in humans (Plourde et al., 2008). Scientists have 
postulated that the health effects of CLA may be 
isomer-dependent and divergent in their effects (Roche 
et al., 2002; Arbonés-Mainar et al., 2006; Yeganeh et 
al., 2016). The majority of studies investigating the 
anti-inflammatory potential of CLA consumption have 
focused on cis-9,trans-11 CLA. Table 2 highlights some 
of the studies that have focused on human consump-
tion of dairy products enriched in CLA and their ef-
fect on the concentration of inflammatory markers and 
hemorheological values.
Sofi et al. (2010) concluded that the consumption of 
cis-9,trans-11 CLA in ewe cheese had a beneficial effect 
on risk factors associated with CVD. Although they 
observed no significant changes in the lipid profile of 
the participants during the intervention phase, they did 
see a significant reduction of inflammatory cytokines 
and platelet aggregation induced by arachidonic acid. 
Although the results were from a limited study group, 
this promising evidence suggests that the consumption 
of cis-9,trans-11 CLA from pecorino cheese may reduce 
the inflammatory response and prevent subsequent ath-
erosclerosis and related inflammatory diseases.
The majority of the studies presented in Table 2 
used CLA concentrations of less than 3 g/d. Studies 
show that high amounts of CLA (approximately 3 to 
3.2 g/d) are required to yield plasma concentrations 
of CLA and metabolites sufficient to exert nutritional 
effects in experimental animal models (Mele et al., 
2013; Rodríguez-Alcalá et al., 2013). However, Raff et 
al. (2008) have hypothesized that the necessary level 
may be over 10 times higher in reality. It is plausible 
that the concentrations of CLA used in the studies in 
Table 2 were not high enough to exert beneficial effects, 
although this was not the case for the Sofi et al. (2010) 
study, in which participants consumed approximately 
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0.45 g/d. More clinical studies are required to confirm 
whether the consumption of CLA has a beneficial effect 
for chronic systemic inflammation.
The n-6/n-3 PUFA ratio has also dominated research 
in recent years. We have evolved to consume n-6/n-3 
PUFA in a 1:1 ratio. This ratio has increased dramati-
cally, with estimates suggesting a ratio closer to 15:1 or 
17:1 (Simopoulos, 2002a). The marked increase in n-6 
PUFA consumption is due to our evolution of mecha-
nized food production over the last 100 years, charac-
terized by increased meat and cereal consumption rich 
in arachidonic acid and n-6 PUFA, and leading to a 
decrease in consumption of n-3 fatty acids (Simopou-
los, 2002a). This ratio imbalance has been associated 
with the pathogenesis of several inflammatory diseases 
(Simopoulos, 2002b; Simopoulos, 2004). Recent re-
search by Simopoulos (2016) has found that this ratio 
imbalance may also coincide with a greater risk of obe-
sity, which further exacerbates chronic inflammatory 
diseases and leads to poorer health. Numerous studies 
and reviews have highlighted the potential benefits of 
n-3 long-chain PUFA (LC-PUFA) supplementation 
from marine sources to prevent chronic inflammatory 
diseases (Calder, 2002; Wall et al., 2010). Conventional 
dairy products are naturally low in n-3 LC-PUFA 
(Dawczynski et al., 2009), and this has led to an in-
terest in meeting our dietary requirements by altering 
the diets of dairy-producing animals, enriching dairy 
products directly. Many studies have enhanced the 
lipid composition of dairy products by adding bioac-
tive compounds, oils, and fats from plant and marine 
sources in the production of yogurt (Espírito Santo et 
al., 2010; Georgakouli et al., 2016; Robertson et al., 
2016). Table 3 presents studies that focus on the effects 
of dairy products enriched with PUFA on inflammatory 
markers in humans.
Dawczynski et al. (2009) investigated the effects of 
n-3 LC-PUFA–enriched dairy product consumption 
on inflammatory markers in patients with rheuma-
toid arthritis. Consumption of these supplemented 
dairy products improved several immunological and 
hemorheological markers, possibly benefiting rheuma-
toid arthritis patients, because they have increased 
risks of CVD due to prolonged elevation of C-reactive 
protein and poor vascular function (Peters et al., 2010). 
The same authors also studied how the consumption 
of n-3 LC-PUFA–supplemented dairy products affected 
mildly hypertriacylglycerolemic patients in relation 
to CVD[AU1: Please supply a reference for this 
study.]. These products resulted in more favorable 
blood lipid parameters, no evidence of oxidative DNA 
damage, and a higher n-3 fatty acid index.
Dawczynski et al. (2013) further assessed these 
PUFA–enriched products by conducting a randomized, 
placebo-controlled intervention study using n-3 LC-
PUFA–supplemented yogurts. Consumption of these 
enriched dairy products resulted in a dose-dependent 
improvement of cardiovascular risk factors such as the 
n-3 fatty acid index, high-density lipoprotein cholester-
ol levels, triacylglycerols, low-/high-density lipoprotein 
cholesterol ratios, and arachidonic acid/eicosapentae-
noic acid ratios in blood plasma and red blood cells of 
hypertriacylglycerolemic participants (Tholstrup et al., 
2006).
These ex vivo studies focused mainly on non-healthy 
participants and have highlighted inconsistencies in 
confirming the links between dairy fat intake and in-
flammatory markers. Many of these discrepancies are 
due to the type of study design employed, the sources 
of milk used, and the processes used to create the dairy 
products. A study investigating the effect of dairy 
consumption on biomarkers of inflammation in healthy 
participants by Labonté et al. (2014) observed that 
short-term consumption of a combination of low-fat 
milk, low-fat yogurt, and regular-fat cheese had no ef-
fect on circulating inflammatory markers. As previously 
stated, researchers who limited their investigations to 
low-fat dairy consumption essentially disregarded the 
influence of the lipid fraction on inflammatory mark-
ers and did not obtain an accurate indication of their 
potential health effects.
Chronic inflammation persists in those who are 
obese due to the increased mass of adipose tissue and 
resulting increase in adipokines. This significantly con-
tributes to endothelial dysfunction and CVD develop-
ment (Guarner and Rubio-Ruiz, 2014). The elderly are 
also vulnerable to chronic inflammatory diseases such 
as metabolic syndrome and CVD because of elevated 
inflammatory markers and insulin levels due to im-
munosenescence, obesity, and sarcopenia (Guarner and 
Rubio-Ruiz, 2014). Rashidi Pour Fard et al. (2015) re-
ported that total dairy consumption was not associated 
with lower C-reactive protein or increased risk of insulin 
resistance in a study of 107 elderly participants. A large 
cohort study by Wennersberg et al. (2009), reported 
no decrease in the level of inflammatory biomarkers in 
obese participants with metabolic syndrome who raised 
their consumption of dairy foods from habitual levels 
of consumption.
Although these studies are reassuring that dairy con-
sumption is not associated with an increase in systemic 
inflammation, more research is required to discern 
whether the dairy products—and in particular the lipid 
fractions—have anti-inflammatory properties. The ex 
vivo studies presented here show that more research is 
required to decipher: (a) what exact dairy products and 
their lipid components are involved in the modulation 
of inflammatory biomarkers; (b) what concentrations 
8 LORDAN AND ZABETAKIS
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of these lipids are required to have a beneficial effect, 
and are they bioavailable; (c) whether the source of 
these bioactive lipids matters (bovine, ovine, caprine, 
or fortified/enriched products); and (d) what potential 
health implications are associated with the consump-
tion of these dairy lipids.
Epidemiological
Epidemiological studies generally report overall dairy 
consumption and are not designed to give specific 
information about certain micronutrients or specific 
products. These studies commonly disregard the mea-
surement of inflammatory markers over long periods 
because of the costs and logistical problems related 
to assessing large cohorts. Table 4 highlights several 
cohort studies that have scrutinized the consumption 
of dairy products relative to the risk of chronic inflam-
matory diseases, with an emphasis on CVD. Elwood 
et al. (2004b) identified 10 studies that estimated the 
intake of milk or calcium from dairy sources in rela-
tion to incidence of ischemic heart disease and ischemic 
stroke, and the cohort of studies provided no convinc-
ing evidence that milk consumption was harmful. In 
fact, the most recent studies in both Table 4 and 5 as 
a whole suggest that milk intake may be associated 
with a modest reduction in heart disease and stroke 
risk. Meta-analyses of dairy consumption also generally 
report that dairy is inversely associated with inflam-
matory diseases such as CVD (Alexander et al., 2016), 
metabolic syndrome (Chen et al., 2015), type 2 diabetes 
(Chen et al., 2014), and cancer (Li et al., 2011; Larsson 
et al., 2015). The evidence is mounting to re-evaluate 
our stance on the consumption of dairy products with 
respect to inflammatory diseases. It is also important 
that epidemiological study designs include the evalua-
tion of inflammatory markers to decipher what foods 
might exacerbate inflammatory conditions.
The ATTICA study (Panagiotakos et al., 2010) in-
vestigated how the consumption of dairy products af-
fects levels of inflammatory markers in blood samples 
from fasting adults who had no evidence of previous 
chronic inflammatory disease. After adjusting for po-
tential confounders, levels of inflammatory markers 
such as C-reactive protein, IL-6, and TNF-α were 29, 
9, and 20% lower, respectively (P = 0.01), in people 
who consumed more than 14 servings of dairy per week 
compared with those who had fewer than 8 servings 
per week (P = 0.05). This inverse association between 
dairy consumption and levels of inflammatory markers 
in healthy adults indicates that dairy products may be 
protective against chronic inflammatory diseases.
Cohort studies have several limitations, because they 
are usually conducted in homogeneous populations who 
share a similar diet, lifestyle, and are from the same 
geographical region. Therefore, they may not apply to 
populations from other geographical regions. Wang et 
al. (2015) conducted such a study and elucidated an 
inverse association between low consumption of dairy 
products (1 to 2 times a month) in men and all-cause 
mortality. However, they found lower all-cause mortal-
ity only found in women who drank dairy products 3 
to 4 times a week. These levels of dairy consumption 
were very low and not comparable to Western societies. 
Milk and dairy intake in Japan has been much lower 
than in Europe and Western countries, with liquid milk 
accounting for 92.1% of the total Japanese dairy intake 
in the 1990s (Wang et al., 2015). Similar studies have 
demonstrated the benefits of dairy product consumption 
in Japanese cohorts, including lower insulin resistance 
due to full-fat dairy product intake (Akter et al., 2013) 
and lower CVD risk in women who consumed mainly 
low-fat milk (Kondo et al., 2013). These studies may be 
useful for defining dietary recommendations in Asian 
societies, but not in Western societies. Many of the 
studies presented in Tables 4 and 5 are from Western 
countries, which represent some of the most recognized 
studies examining the effects of dairy product con-
sumption. The participants recruited in these studies 
consumed dairy products on a regular basis, and their 
diets included yogurt and cheese, not just liquid milk. 
Although yogurt and cheese are derived from milk, they 
have similar and varied effects on health compared to 
milk intake. The participants of the studies in Tables 
4 and 5 also consumed dairy products more regularly 
than in the study by Wang et al. (2015). Thus, the 
study by Wang et al. (2015) is not applicable to other 
countries where people consume dairy products on a 
regular basis.
In epidemiological studies, researchers often exam-
ined the health effects of low-fat dairy products over 
full-fat products, despite the limitations of such an ap-
proach as discussed above. Louie et al. (2013) found no 
consistent association between dairy intake and the risk 
of coronary heart disease, stroke, or CVD mortality in a 
population that ingested low-fat dairy products. There 
is currently no consensus on whether low-fat dairy prod-
ucts are associated with a lower risk of CVD (Benatar 
et al., 2013). Although low-fat dairy products are them-
selves nutrient-dense and have lowering effects on blood 
pressure (Appel et al., 1997; van Meijl and Mensink, 
2011), more research is required to deduce whether 
these findings are similar for full-fat dairy products. As 
epidemiological research progresses, analyzing low-fat 
and full-fat dairy products separately compared with a 
control may allow for accurate indication of the effects 
of dairy products on human health. This will also allow 
researchers to design more in-depth studies to decipher 
10 LORDAN AND ZABETAKIS
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the pro- or anti-inflammatory mechanisms of lipids and 
other macronutrients. A credible approach could be the 
use of metabolomics to assess different dietary patterns 
and biomarkers (O’Sullivan et al., 2011). Advantages to 
these methodologies include reducing human error and 
subjective bias due to errors in reporting dietary intake 
and the misclassification of foods (Favé et al., 2009). 
However, specific and definitive markers for dairy con-
sumption still need to be identified, and models capable 
of quantifying dairy intake based on the analysis of bio-
logical samples are still warranted (Zheng et al., 2015).
FUTURE RESEARCH AVENUES AND CONCLUSIONS
In this review, we have discussed the anti-inflamma-
tory properties of dairy-derived bioactive lipids. We 
have examined certain limitations (i.e., how the anti-
inflammatory activity of certain lipid fractions in dairy 
products have yet to be fully characterized, largely due 
to the negative perception of fat in dairy products) and 
have proposed that the polar lipid fractions of dairy 
products are overlooked, probably because they con-
stitute <1% of the total lipid content of most dairy 
products, despite their strong anti-inflammatory activi-
ties (Megson et al., 2016). Globally, ongoing research is 
focused on the structural elucidation of cardioprotec-
tive lipids. Current trends are toward the production 
of products with enhanced activities against CVD, 
cancer, and obesity.
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